Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics

Gracell Biotechnologies Inc. (GRCL): $3.08

0.10 (+3.36%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add GRCL to Watchlist
Sign Up

Industry: Beverages

Industry

A

Ranked

#23 of 37

in industry

GRCL Price/Volume Stats

Current price $3.08 52-week high $5.69
Prev. close $2.98 52-week low $1.40
Day low $2.88 Volume 80,640
Day high $3.09 Avg. volume 269,267
50-day MA $2.08 Dividend yield N/A
200-day MA $2.48 Market Cap 208.56M

GRCL Stock Price Chart Interactive Chart >


Gracell Biotechnologies Inc. (GRCL) Company Bio


Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.


GRCL Latest News Stream


Event/Time News Detail
Loading, please wait...

GRCL Latest Social Stream


Loading social stream, please wait...

View Full GRCL Social Stream

Latest GRCL News From Around the Web

Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.

Q1 2023 Gracell Biotechnologies Inc Earnings Call

Q1 2023 Gracell Biotechnologies Inc Earnings Call

Yahoo | May 16, 2023

Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced that it will host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am ET. Gracell Biotechnologies’ KOL event will feature participation from management and key

Yahoo | May 15, 2023

Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced the initiation of an investigator-initiated trial (IIT) in China of GC012F, the Company's autologous FasTCAR therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, for the treatment of refractory SLE.

Yahoo | May 15, 2023

Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update

Presenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and EHA2023On track to commence a Phase 1b/2 clinical trial in U.S. and a Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the second quarter and third quarter of 2023, respectivelyLaunched the new IIT evaluating GC012F in systemic lupus erythematosus (SLE)Presenting updated d

Yahoo | May 15, 2023

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online. Clinical data from GC012F, the Company's FasTCAR-enable

Yahoo | May 11, 2023

Read More 'GRCL' Stories Here

GRCL Price Returns

1-mo 57.95%
3-mo 52.48%
6-mo -6.67%
1-year 12.82%
3-year N/A
5-year N/A
YTD 33.91%
2022 -61.92%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!